Amber Tong is a Reporter at various esteemed publications including NXTmine and The Boston Globe. She covers a diverse range of topics with a focus on health and wellness, healthcare technology, and finance, often exploring themes related to digital health and medical equipment innovations. Amber's work has been featured in notable outlets such as Bloomberg News, Fortune, and the Los Angeles Times.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Amber's coverage mainly focuses on healthcare and pharmaceuticals, with a significant emphasis on company announcements and clinical trial outcomes. She appears to be particularly interested in developments within the pharmaceutical industry, including drug development, clinical trials, and company acquisitions.
Given her focus on private sector announcements and press releases, Amber may be more responsive to pitches related to exclusive news from within the pharmaceutical industry or expert insights into major developments such as clinical trial results or company strategies.
It is important to note that Amber does not seem to have a specific geographic focus but rather provides comprehensive coverage of global pharmaceutical industry developments.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Amber Tong, Karen Leigh
CSL Ltd. forecast no revenue growth and underlying net profit after tax growth of about 5% at constant currency for fiscal 2027, signaling another subdued year as Australia’s largest health-care company pushes ahead with a sweeping restructuring.
For US drugmakers, the expanding tie-ups with Chinese companies mean lower costs and more access to breakthrough treatments. For critics in Washington, the deals spell risk.
An experimental lung disease drug developed using artificial intelligence showed promise in reversing biological signs of aging, pointing to broader potential use of the treatment, according to its developer.
Un fármaco desarrollado con IA redujo hasta seis años la edad biológica y abre nuevas posibilidades para combatir el envejecimiento.
An experimental lung disease drug developed using artificial intelligence showed promise in reversing biological signs of aging, pointing to broader potential use of the treatment, according to its developer.
Novo Nordisk A/S will pay as much as $2.6 billion to license an experimental obesity pill from China’s Jiangsu Hengrui Pharmaceuticals Co., adding an early-stage drug to its pipeline as it seeks to rebuild investor confidence in its future beyond blockbusters Ozempic and Wegovy.
Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.
US biotech ArriVent Biopharma’s late-stage failure for its lung cancer drug is likely to stall the therapy’s global prospects and deepen scrutiny of medicines developed in China.
By: Manuel Baigorri, Julia Fioretti, Amber Tong
Suzhou Sanegene Bio Inc. is targeting next year for a Hong Kong initial public offering after confidentially filing for the deal, according to people familiar with the matter.
China is looking to tighten biotechnology exports, but will leave the door open for licensing deals with foreign drugmakers that have underpinned its position as a growing pharmaceutical powerhouse.
